Biochemical Markers for Human Cancer

Chu, Tang–Yuan

doi:10.1007/978-3-642-71356-9_2

Cited by 17 publications

(10 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Classically, cellular prostatic acid phosphatase (cPAcP) is used as a biomarker of the tissue origin for metastasized prostate cancer cells, and secreted PAcP serves as a serological marker for the diagnosis of the cancer (Chu et al, 1982;Chu and Lin, 1998). However, it should be noted that in prostate carcinomas, cPAcP expression is decreased, much lower than that in noncancerous prostate cells (Loor et al, 1981;Lin et al, 1983Lin et al, , 2001Solin et al, 1990).…”

Section: Introductionmentioning

confidence: 99%

Tyrosine-317 of p52Shc mediates androgen-stimulated proliferation signals in human prostate cancer cells

2004

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Tyrosine-317 of p52Shc mediates androgen-stimulated proliferation signals in human prostate cancer cells

2004

View full text Add to dashboard Cite

“…AFP elevation is also seen in patients with nonseminomatous and germ cell tumors of the ovary and testis [43]. AFP and HCG used together are very sensitive in the monitoring of therapy in patients with these germ cell tumors.…”

Section: Alphafetoproteinmentioning

confidence: 99%

“…With its recognition in 1938, the relationship between an elevated acid phosphatase and carcinoma of the prostate demonstrated one of the earliest uses of tumor markers [88]. Prostatic acid phosphatase (PAP) is a 100,000 dalton glycoprotein normally found in the prostate gland and its secretions [43,54,60]. Its presence in serum is determined by either radioimmunoassay or a counterimmunoelectrophoresis by using a specific antibody against PAP [54,89].…”

Section: Prostate Cancer Markers Prostatic Acid Phosphatasementioning

confidence: 99%

Present status of serum markers

Minton

Chevinsky

1989

Seminars in Surgical Oncology

View full text Add to dashboard Cite

Tumor markers presently in use generally meet only one or two of the criteria for the ideal marker, which are: tumor specificity, correlation with tumor bulk and stage of the disease, decrease to normal after successful treatment, and rise prior to clinical manifestations of recurrence. In addition, virtually all are elevated in some benign conditions. Currently their greatest usefulness is for confirmation of clinical suspicion and for monitoring known disease. Some tumor markers which are not effective as screening tests can be used to evaluate the patient's response to therapy. The discovery of oncogenes holds great promise for a new generation of tumor markers. Major breakthroughs in the fields of molecular biology and tumor immunology seem imminent with eventual application possibly in the treatment of cancer.

show abstract

“…The spectrum of biochemical tumor markers reported to date is very wide. [1][2][3][4][5] DEFINITIONS "A tumor marker is a substance present in or produced by a tumor or by the tumor's host in response to the tumor's presence that can be used to differentiate a tumor from normal tissue or to determine the presence of a tumor based on measurement in the blood or secretions." [6] Tumor markers can also be defined as "specific, novel or structurally altered cellular macromolecules or temporarily spatially or quantitatively altered normal molecules that are associated with malignant (and in some cases benign) neoplastic cells."…”

Section: Introductionmentioning

confidence: 99%